JUN 18, 2019 8:19 AM PDT

Scientists Identify Which Gut Bacteria Interfere With Parkinson's Treatment

WRITTEN BY: Tiffany Dazet

A new study from a team of Harvard scientists discovered one of the first distinct examples of how gut bacteria can interfere with a drug’s pathway through the body. Out of the trillions of possible culprits, the team was able to identify which bacteria degrade the drug and how to stop the interference.

The study, recently published in Science, focused on levodopa (L-dopa), which has been the primary treatment for Parkinson’s disease for the past 50 years. L-dopa relieves Parkinson’s symptoms by delivering dopamine to the brain. However, it is estimated that only about one to five percent of the drug actually reaches the brain.

When the L-dopa metabolizes outside the brain, the resulting dopamine causes side effects, including severe gastrointestinal distress and cardiac arrhythmias. In addition, patients are often given higher doses of the drug to combat symptoms, possibly intensifying these side effects. 

To increase the efficacy of L-dopa, a new drug to block the L-dopa metabolism—carbidopa—was introduced, and the combination of the pills seemed to help Parkinson’s patients. Although this solution exists, the research team wanted to dig deeper and discover the unexplained drug metabolism and reasons for efficacy variance between patients.

Using data from the Human Microbiome Project, the team was able to identify specific enzymes produced by two different bacterial species that work together to digest L-dopa in the human gut. Enterococcus faecalis absorbs L-dopa and converts it to dopamine while Eggerthella lenta converts dopamine into meta-tyramine, which may be responsible for L-dopa’s side effects.

In a statement from Harvard’s Department of Chemistry and Chemical Biology, lead author Professor Emily Balskus stated that “all of this suggests that gut microbes may contribute to the dramatic variability that is observed in side effects and efficacy between different patients taking L-dopa.”

Using mice, the research team also identified a small molecule—alpha-fluoromethyltyrosine (AFMT)—that could block this particular metabolic pathway, thereby increasing the efficacy of L-dopa in Parkinson’s patients. Although this may result in Parkinson’s patients requiring a third drug for treatment, Balskus stated that their discovery “opens up the door to the possibility of developing a new class of therapeutics to improve patient response to L-dopa—that would be drugs targeting gut microbe metabolism in addition to targeting host metabolism.”

Sources: Harvard, Science Magazine, New Scientist

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
APR 29, 2020
Clinical & Molecular DX
APR 29, 2020
Move and Detect : Diagnosis of Neonatal Sepsis Using Fluorescent Micromotors
According to the World Health Organization (WHO), sepsis occurs when the body’s response to an infection injures i ...
APR 29, 2020
Microbiology
APR 29, 2020
Bacteria Exposed to Antibiotics are 'Primed' to Gain More Resistance
Antibiotics are critical drugs that have saved millions of lives, but bacteria can also gain resistance to them, renderi ...
MAY 03, 2020
Cell & Molecular Biology
MAY 03, 2020
How One Protein is Linked to Three Different Brain Disorders
The accumulation of aberrant, misfolded proteins is a known feature of several different kinds of brain diseases.
MAY 04, 2020
Cancer
MAY 04, 2020
A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy
Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These trea ...
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
MAY 23, 2020
Cancer
MAY 23, 2020
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These ...
Loading Comments...